10-Q: cbdMD Inc. Reports Q3 2024 Results, Focuses on Cost Reduction and Revenue Growth

cbdMD, Inc. reported its Q3 2024 financial results, highlighting a focus on cost reduction and revenue growth initiatives despite a year-over-year decrease in net sales.

Summary

• cbdMD, Inc. reported a net loss of $540,763 for the three months ended June 30, 2024, compared to a net loss of $2,770,904 for the same period in 2023.
• Net sales for the quarter were $5,173,878, a decrease from $6,119,380 in the prior year's quarter.
• The company's gross profit margin increased to 65.8% from 62.8% year-over-year.
• Operating expenses decreased significantly to $3,785,542 from $5,669,193 in the same quarter of the previous year.
• For the nine months ended June 30, 2024, the net loss attributable to common shareholders was $6,548,828, compared to $10,064,773 for the same period in 2023.
• The company's cash and cash equivalents were $2,395,175 as of June 30, 2024.
• The company has a working capital deficit of $567,610 as of June 30, 2024.
• The company issued convertible notes for $1,250,000 in gross proceeds during the quarter.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive signs of cost reduction and strategic initiatives, the company is still facing significant challenges with revenue growth, profitability, and its capital structure. The risk of delisting from the NYSE American is also a major concern.

Positives

• The company's gross profit margin improved year-over-year.
• Operating expenses were significantly reduced, indicating successful cost-cutting measures.
• The company is focusing on product innovation and expanding revenue channels.
• The company is exploring international expansion opportunities.
• The company is actively working to improve its capital structure.
• The company has made significant progress in reducing its monthly cash burn.
• The company has launched new product lines, including the ATRx functional mushroom line.

Negatives

• Net sales decreased year-over-year, indicating a continued challenge in revenue growth.
• The company reported a net loss for the quarter and nine-month period.
• The company has a working capital deficit, raising concerns about its short-term financial health.
• The company is facing challenges with its current capital structure, specifically the Series A Preferred stock.
• The company received a notice from the NYSE American regarding non-compliance with continued listing standards.
• The company has suspended paying cash dividends to preferred shareholders.

Risks

• The company's ability to continue as a going concern is dependent on improving profitability and acquiring additional funding.
• The company is not in compliance with NYSE American continued listing standards and may be delisted if it does not regain compliance.
• The company's working capital position may not be sufficient to support daily operations for the next twelve months.
• The company faces risks related to the regulatory environment for CBD products.
• The company relies on third-party suppliers and manufacturers, which could pose supply chain risks.
• The company's reliance on key digital channels for marketing could be a risk if those channels become less effective.
• The company's inability to pay dividends on its Series A Convertible Preferred Stock could impact investor confidence.

Future Outlook

The company anticipates increasing marketing spend during the fourth fiscal quarter to offset some of the savings from cost-cutting initiatives. Management believes the quarterly cash consumption should continue to improve in subsequent quarters. The company is focused on growing revenue and operating with lean infrastructure costs.

Management Comments

• Management continues to be very focused on our goal of delivering positive earnings through a combination of optimizing our product portfolio, right-sizing our cost structure and investing in marketing that will provide positive return on customer acquisition.
• Management continues to focus on growing revenue and operating with lean infrastructure costs.
• Management made a strategic decision to work with GNC on an exclusive initial launch of the Platinum line to help offset some legacy inventory issues.
• We believe the combined market capitalization of both our common and Series A Preferred is being impacted due to our current capital structure.
• Our goal is to simplify our capital structure and we believe it will help unlock additional equity value and open up more strategic activity for the Company.

Industry Context

The company operates in the competitive CBD and functional mushroom market. The company is focusing on product innovation, expanding revenue channels, and international expansion to gain a competitive edge. The company is also working to address the challenges of the current regulatory environment for CBD products.

Comparison to Industry Standards

• The company's gross profit margin of 65.8% is relatively strong compared to some other companies in the consumer packaged goods industry, but it is important to compare this to other CBD companies specifically.
• The company's operating expense reduction is a positive sign, as many companies in the CBD space have struggled with high operating costs.
• The company's net loss is still a concern, as many companies in the CBD industry are still working towards profitability.
• The company's cash position is relatively low, which is a common challenge for smaller companies in the CBD industry.
• The company's focus on product innovation and expanding revenue channels is in line with industry best practices.
• The company's international expansion efforts are also a positive sign, as many companies in the CBD industry are looking to expand into new markets.
• The company's challenges with its capital structure are not unique, as many companies in the CBD industry have struggled with raising capital.

Stakeholder Impact

• Shareholders are impacted by the company's net loss and the risk of delisting from the NYSE American.
• Employees are impacted by the company's cost-cutting measures, including headcount reductions.
• Customers may be impacted by the company's product innovation and expansion of revenue channels.
• Suppliers may be impacted by the company's focus on cost reduction.
• Creditors may be impacted by the company's working capital deficit and its ability to repay its debts.

Next Steps

• The company will continue to focus on cost reduction and revenue growth initiatives.
• The company will work to regain compliance with NYSE American continued listing standards.
• The company will continue to explore international expansion opportunities.
• The company will continue to evaluate M&A opportunities.
• The company will continue to focus on product innovation and expanding revenue channels.

Key Dates

Keywords

CBD, cannabidiol, hemp, financial results, cost reduction, revenue growth, e-commerce, wholesale, ATRx, functional mushrooms, convertible notes, operating expenses, net loss, NYSE American, listing standards